Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in United States has been experiencing steady growth in recent years.
Customer preferences: The increasing prevalence of rheumatoid arthritis and other rheumatic diseases among the aging population in the United States has been a major driver of demand for Anti-Rheumatic Drugs. Additionally, the growing awareness about the benefits of early diagnosis and treatment of these diseases has led to an increase in demand for these drugs.
Trends in the market: One of the major trends in the Anti-Rheumatic Drugs market in the United States is the increasing use of biologic drugs. These drugs are designed to target specific parts of the immune system that are involved in the development of rheumatic diseases. They have been found to be more effective than traditional disease-modifying anti-rheumatic drugs (DMARDs) in managing symptoms and slowing down the progression of the disease.Another trend in the market is the growing preference for self-administered drugs. Patients are increasingly opting for drugs that can be self-administered at home, rather than having to visit a healthcare facility for treatment. This trend has been fueled by the availability of easy-to-use injectable devices and the growing comfort level of patients with self-administration.
Local special circumstances: The United States has a well-developed healthcare system, with a high level of access to healthcare services. This has led to a high level of awareness about rheumatic diseases and the availability of treatment options. Additionally, the country has a large pharmaceutical industry, which has led to a high level of innovation and competition in the Anti-Rheumatic Drugs market.
Underlying macroeconomic factors: The United States has a strong economy, which has led to a high level of disposable income among the population. This has allowed patients to afford the high cost of biologic drugs, which are often more expensive than traditional DMARDs. Additionally, the country has a strong research and development sector, which has led to the development of new and innovative drugs for the treatment of rheumatic diseases.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
